Sign in
Enrolling by invitationNo phase

Long-term health follow-up of Chinese people with myotonic dystrophy type 1

Tracks how myotonic dystrophy type 1 affects Chinese patients' health.

Key facts

Who runs it
Huashan Hospital
Where
China22 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Chinese Multicenter Clinical Outcome Cohort Study of Myotonic Dystrophy Type 1 (C-DMCOS-DM1)
Status
Enrolling by invitation
People taking part
1,000 people, planned
Started
1 Aug 2021
Expected to end
30 Dec 2035
Type of study
Observational
Treatments tested
  • MRI scan
  • Electrocardiography
  • Pulmonary function test
  • Electrocardiography and 24-hour Holter monitoring
  • Skeletal muscle biopsy (residual specimen)
  • Wearable-device continuous physiological monitoring
  • Video and voice recording for AI analysis
Record updated
2 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Chinese people with myotonic dystrophy type 1 (DM1), confirmed by a genetic test. It follows them over time and does not test a new treatment.

Age
The record gives no age limits. Minors can join with consent signed by a legal guardian.
Sex
All sexes can join.
Disease stage
Myotonic dystrophy type 1 confirmed by a genetic test.
Biomarker or test result
CTG repeat expansion in the 3' untranslated region of the DMPK gene.

Main reasons for not taking part

  • Pregnancy, because of MRI safety
  • Unable to follow the study procedures
  • Unable to give informed consent, or the guardian says no
  • A severe, unstable medical condition that prevents the study tests

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Genetically confirmed DM1 (CTG repeat expansion in the 3' untranslated region of the DMPK gene)
  • Any sex
  • Able to attend regular follow-up and willing to provide and store residual blood, urine, and other biospecimens for research
  • Voluntary participation with signed informed consent (signed by legal guardian for minors)
  • Consent to use of routine clinical, examination, and follow-up data for research

Who cannot take part

  • Severe, unstable medical condition that precludes assessments
  • Unable to comply with study procedures
  • Unable to provide informed consent, or guardian declines participation
  • Pregnancy (for MRI safety)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Myotonic dystrophy type 1 (DM1) is an autosomal dominant multisystem disorder caused by an expanded CTG trinucleotide repeat in the 3' untranslated region of the DMPK gene. Beyond myotonia and progressive skeletal muscle weakness, DM1 involves the cardiac, respiratory, central nervous, gastrointestinal, endocrine, and ocular systems, and respiratory and cardiac involvement are the leading causes of disability and death. Systematic, long-term outcome data in Chinese DM1 patients are lacking.

Read full original descriptionShow less

C-DMCOS-DM1 is a multicenter, prospective, observational cohort study that systematically records demographic data, multisystem involvement, and predefined disability-related clinical outcome events in genetically confirmed Chinese DM1 patients, with regular follow-up every 3 to 6 months. The study also collects residual blood, skeletal muscle, myocardium (when a pacemaker is implanted), and urine specimens for transcriptomic and other molecular studies. The aims are to characterize the disease burden of Chinese DM1 patients, identify risk and prognostic factors for disabling outcomes, and build risk-prediction models to inform follow-up, management, and future clinical trials.

The group in the trial

  • DM1 patients

    Patient cohort

    Treatment: MRI scan, Electrocardiography, Pulmonary function test, Electrocardiography and 24-hour Holter monitoring, Skeletal muscle biopsy (residual specimen), Wearable-device continuous physiological monitoring, and Video and voice recording for AI analysis

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Multicenter, Prospective, Observational Cohort Study of Multi-System Involvement and Disability-Related Clinical Outcomes in Chinese Patients With Myotonic Dystrophy Type 1 (C-DMCOS-DM1)
Plain-language title
Long-term health follow-up of Chinese people with myotonic dystrophy type 1Generated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
2 June 2026